WallStSmart

Enovis Corp (ENOV)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1457% more annual revenue ($35.48B vs $2.28B). MDT leads profitability with a 13.0% profit margin vs -49.9%. MDT appears more attractively valued with a PEG of 1.29. MDT earns a higher WallStSmart Score of 61/100 (C+).

ENOV

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 3.0Value: 6.3Quality: 5.5
Piotroski: 4/9Altman Z: -0.34

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENOVUndervalued (+34.9%)

Margin of Safety

+34.9%

Fair Value

$35.03

Current Price

$23.78

$11.25 discount

UndervaluedFair: $35.03Overvalued
MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENOV2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

EPS GrowthGrowth
153.1%10/10

Earnings expanding 153.1% YoY

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

ENOV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Market CapQuality
$1.25B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.6%3/10

Operating margin of 3.6%

Return on EquityProfitability
-77.0%2/10

ROE of -77.0% — below average capital efficiency

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENOV

The strongest argument for ENOV centers on Price/Book, EPS Growth.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : ENOV

The primary concerns for ENOV are PEG Ratio, Market Cap, Operating Margin.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ENOV profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

ENOV carries more volatility with a beta of 1.49 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 57/100). ENOV offers better value entry with a 34.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Enovis Corp

HEALTHCARE · MEDICAL DEVICES · USA

Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?